>If MNTA signed the deal calling for anything more than a marginally lower profit share should Sanofi launch an authorized generic, that was a major gaffe.<
That’s unduly harsh.
When the Lovenox deal with Sandoz was announced in Nov 2003, MNTA was only two years old and its technology was little known outside of MIT. Yet MNTA was still able to ink a deal where Sandoz pays 100% of the development and commercialization costs and MNTA garners about 45% of the net profits if there is only one approved generic.
The takedown in MNTA’s profit share in the event of an AG launch by Sanofi is an unusual feature, but it hardly qualifies as a “major gaffe” IMO.
Market Data 
Markets 
AI
